Stem cell therapies for CHD have demonstrated encouraging biologic signals and generally reassuring early safety data, and the collective findings suggest potential translational applicability of regenerative therapy in the management of congenital heart diseases.
This review examines the heritable underpinnings of CAD, focusing on the contributions of GWAS to the understanding of the disease, and highlights how GWAS findings are paving the way for personalized medicine through polygenic risk scores, targeted therapies, and pharmacogenomics-driven interventions for CAD.
Shruti Tomar, Vikas Kumar· Current Cardiology Reviews· 0 citations
This review synthesizes current evidence, highlights translational challenges, and explores emerging directions, including biomaterial-assisted delivery and precision medicine-based patient stratification, which may enable stem cell therapies to become a viable adjunct in managing NICM.